Browse All

Current Filters

CLEAR FILTER x

TITLE

Author:

Patterns of Medication Utilization and Migraine Frequency in Adults Using Rimegepant for Both Preventive and Acute Treatment for Migraine: Results From a 52-Week, Open-Label Extension Study

Beyond migraine headache day reduction: Clinically meaningful improvement in disability (MIDAS score) in the absence of greater than 50% reductions in monthly migraine days with galcanezumab

Continuing Medical Education Increases Knowledge, Competence, and Confidence Related to the Use of Non-Oral Acute Migraine Therapies Among Neurologists